Nanoviricides (NNVC) Other Non-Current Assets (2013 - 2023)
Nanoviricides' (NNVC) quarterly Other Non-Current Assets came in at $14361.0 in Q2 2023, down 66.16% year-over-year from $42440.0 in Q2 2022, and down 25.14% quarter-over-quarter from $19183.0 in Q1 2023.
Analysis
Nanoviricides (NNVC) Other Non-Current Assets (2013 - 2023) Analysis & Trends
Nanoviricides has disclosed Other Non-Current Assets across 11 years of filings, most recently posting $14361.0 for Q2 2023.
- In Q2 2023, Other Non-Current Assets fell 66.16% year-over-year to $14361.0; the TTM figure through Jun 2023 stood at $14361.0 (down 66.16% YoY), while the FY2023 annual figure was $14361.0, down 66.16% from the prior year.
- Other Non-Current Assets came in at $14361.0 for Q2 2023 at Nanoviricides, down from $19183.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $62977.0 in Q3 2020 to a low of $3515.0 in Q1 2021.
- Average Other Non-Current Assets over 5 years is $21966.6, with a median of $20275.0 recorded in 2019.
- Year-over-year, Other Non-Current Assets slumped 94.42% in 2021 and surged 1300.2% in 2022.
- Over 5 years, Other Non-Current Assets stood at $21367.0 in 2019, then sank by 72.61% to $5853.0 in 2020, then sank by 39.95% to $3515.0 in 2021, then soared by 654.2% to $26510.0 in 2022, then slumped by 45.83% to $14361.0 in 2023.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $14361.0 in Q2 2023, $19183.0 in Q1 2023, and $26510.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Nanoviricides | 22.04 Mn | 18.83 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 14,361.00 |
| Mar 31, 2023 | 19,183.00 |
| Dec 31, 2022 | 26,510.00 |
| Sep 30, 2022 | 35,588.00 |
| Jun 30, 2022 | 42,440.00 |
| Mar 31, 2022 | 49,217.00 |
| Dec 31, 2021 | 3,515.00 |
| Sep 30, 2021 | 3,515.00 |
| Jun 30, 2021 | 3,515.00 |
| Mar 31, 2021 | 3,515.00 |
| Dec 31, 2020 | 5,853.00 |
| Sep 30, 2020 | 62,977.00 |
| Jun 30, 2020 | 25,863.00 |
| Mar 31, 2020 | 17,499.00 |
| Dec 31, 2019 | 21,367.00 |
| Sep 30, 2019 | 25,277.00 |
| Jun 30, 2019 | 29,187.00 |
| Mar 31, 2019 | 6,017.00 |
| Dec 31, 2018 | 5,312.00 |
| Sep 30, 2018 | 6,737.00 |